S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
The single greatest medical breakthrough of all time? (Ad)
Stock market today: Wall Street leaps, nearly escapes its bear market after strong jobs report
What Should Investors Make of These 3 Dividend Cuts?
66,000% upside on tiny biotech? (Ad)
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
CrowdStrike: Another Tech Stock to Buy on the Dip 
Pentagon Consultant—Here's how Biden Wins Landslide Re-election (Ad)
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Salesforce: Time to Snap it Up as the Market Buys the Dip?
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
The single greatest medical breakthrough of all time? (Ad)
Stock market today: Wall Street leaps, nearly escapes its bear market after strong jobs report
What Should Investors Make of These 3 Dividend Cuts?
66,000% upside on tiny biotech? (Ad)
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
CrowdStrike: Another Tech Stock to Buy on the Dip 
Pentagon Consultant—Here's how Biden Wins Landslide Re-election (Ad)
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Salesforce: Time to Snap it Up as the Market Buys the Dip?
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
The single greatest medical breakthrough of all time? (Ad)
Stock market today: Wall Street leaps, nearly escapes its bear market after strong jobs report
What Should Investors Make of These 3 Dividend Cuts?
66,000% upside on tiny biotech? (Ad)
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
CrowdStrike: Another Tech Stock to Buy on the Dip 
Pentagon Consultant—Here's how Biden Wins Landslide Re-election (Ad)
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Salesforce: Time to Snap it Up as the Market Buys the Dip?
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
The single greatest medical breakthrough of all time? (Ad)
Stock market today: Wall Street leaps, nearly escapes its bear market after strong jobs report
What Should Investors Make of These 3 Dividend Cuts?
66,000% upside on tiny biotech? (Ad)
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
CrowdStrike: Another Tech Stock to Buy on the Dip 
Pentagon Consultant—Here's how Biden Wins Landslide Re-election (Ad)
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Salesforce: Time to Snap it Up as the Market Buys the Dip?
NASDAQ:XBIT

XBiotech (XBIT) Stock Forecast, Price & News

$5.11
+0.19 (+3.86%)
(As of 06/2/2023 ET)
Compare
Today's Range
$4.88
$5.40
50-Day Range
$3.06
$5.73
52-Week Range
$3.00
$6.49
Volume
75,496 shs
Average Volume
61,489 shs
Market Capitalization
$155.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

XBIT stock logo

About XBiotech (NASDAQ:XBIT) Stock

XBiotech, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutic antibodies. Its product pipeline includes oncology, infectious diseases, dermatology and inflammatory disorders. The company was founded by John Simard on March 22, 2005 and is headquartered in Austin, TX.

Receive XBIT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for XBiotech and its competitors with MarketBeat's FREE daily newsletter.

XBIT Stock News Headlines

XBiotech Inc. (NASDAQ:XBIT) Short Interest Up 23.1% in May
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"
The Washington Post Reports it's: "A revolution in warfare." The Sunday Times Reports it's: "a revolutionary power." Early investors can reap 5,633% gains as England, Germany, Japan and Australia rush to sign contracts. Get the name of the stock here >>>
XBiotech (NASDAQ:XBIT) Coverage Initiated at StockNews.com
XBiotech (NASDAQ:XBIT) Now Covered by StockNews.com
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"
The Washington Post Reports it's: "A revolution in warfare." The Sunday Times Reports it's: "a revolutionary power." Early investors can reap 5,633% gains as England, Germany, Japan and Australia rush to sign contracts. Get the name of the stock here >>>
StockNews.com Upgrades XBiotech (NASDAQ:XBIT) to "Hold"
See More Headlines

XBIT Price History

XBIT Company Calendar

Today
6/02/2023
Next Earnings (Estimated)
6/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XBIT
Employees
97
Year Founded
N/A

Profitability

Net Income
$-32,900,000.00
Net Margins
-820.45%
Pretax Margin
-882.82%

Debt

Sales & Book Value

Annual Sales
$4.01 million
Book Value
$7.78 per share

Miscellaneous

Free Float
21,977,000
Market Cap
$155.55 million
Optionable
Optionable
Beta
1.21

Key Executives

  • John SimardJohn Simard
    Chairman, President & Chief Executive Officer
  • Ashley Otero
    Vice President-Clinical Operations
  • Angela Hu
    Chief Financial & Accounting Officer
  • Sushma Shivaswamy
    Chief Scientific Officer
  • Mark Ziats
    Medical Director













XBIT Stock - Frequently Asked Questions

How have XBIT shares performed in 2023?

XBiotech's stock was trading at $3.51 at the beginning of the year. Since then, XBIT shares have increased by 45.6% and is now trading at $5.11.
View the best growth stocks for 2023 here
.

Are investors shorting XBiotech?

XBiotech saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 83,800 shares, an increase of 23.1% from the April 30th total of 68,100 shares. Based on an average trading volume of 67,700 shares, the days-to-cover ratio is currently 1.2 days. Currently, 0.5% of the shares of the stock are sold short.
View XBiotech's Short Interest
.

When is XBiotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 6th 2023.
View our XBIT earnings forecast
.

What is John Simard's approval rating as XBiotech's CEO?

20 employees have rated XBiotech Chief Executive Officer John Simard on Glassdoor.com. John Simard has an approval rating of 58% among the company's employees. This puts John Simard in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of XBiotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other XBiotech investors own include Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Walt Disney (DIS), Cisco Systems (CSCO), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Intel (INTC), Pfizer (PFE) and Block (SQ).

When did XBiotech IPO?

(XBIT) raised $76 million in an IPO on Wednesday, April 15th 2015. The company issued 4,000,000 shares at a price of $18.00-$20.00 per share. WR Hambrecht + Co served as the underwriter for the IPO.

What is XBiotech's stock symbol?

XBiotech trades on the NASDAQ under the ticker symbol "XBIT."

Who are XBiotech's major shareholders?

XBiotech's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Dimensional Fund Advisors LP (0.25%), Connor Clark & Lunn Investment Management Ltd. (0.19%), Two Sigma Investments LP (0.18%), Renaissance Technologies LLC (0.17%), Two Sigma Advisers LP (0.16%) and Susquehanna International Group LLP (0.13%). Insiders that own company stock include John Simard, Queena Han, Street Financial SA Bay, Sushma Shivaswamy and W Thorpe Mckenzie.
View institutional ownership trends
.

How do I buy shares of XBiotech?

Shares of XBIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is XBiotech's stock price today?

One share of XBIT stock can currently be purchased for approximately $5.11.

How much money does XBiotech make?

XBiotech (NASDAQ:XBIT) has a market capitalization of $155.55 million and generates $4.01 million in revenue each year. The biopharmaceutical company earns $-32,900,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis.

How can I contact XBiotech?

XBiotech's mailing address is 5217 Winnebago Ln, AUSTIN TX, 78744. The official website for the company is www.xbiotech.com. The biopharmaceutical company can be reached via phone at (512) 386-2900, via email at swhitehurst@xbiotech.com, or via fax at 512-386-5505.

This page (NASDAQ:XBIT) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -